User profiles for Diana Giannarelli

Diana Giannarelli

Fondazione Policlinico Universitario A. Gemelli IRCCS Rome
Verified email at policlinicogemelli.it
Cited by 26822

Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial

…, R Grassi, M Franchi, D Giannarelli… - JNCI: Journal of the …, 2008 - academic.oup.com
Background Pelvic lymph nodes are the most common site of extrauterine tumor spread in
early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been …

Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of …

…, A Caliò, F Cuppone, I Sperduti, D Giannarelli… - PloS one, 2015 - journals.plos.org
Background The potential predictive role of programmed death-ligand-1 (PD-L1) expression
on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD…

Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial

…, G Favalli, F Raspagliesi, D Giannarelli… - Journal of the …, 2005 - academic.oup.com
Background: The role of systematic aortic and pelvic lymphadenectomy in patients with
optimally debulked advanced ovarian cancer is unclear and has not been addressed by …

Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter …

…, M Amoroso, D Smaniotto, D Giannarelli… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: Neoadjuvant chemotherapy (NACT) and radical surgery (RS) have emerged as
a possible alternative to conventional radiation therapy (RT) in locally advanced cervical …

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

…, E Fonsatti, O Cutaia, G Amato, D Giannarelli… - The Lancet …, 2013 - thelancet.com
Background Monoclonal antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) have
therapeutic activity in different tumour types. We aimed to investigate the efficacy, safety, and …

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

AM Grimaldi, E Simeone, D Giannarelli, P Muto… - …, 2014 - Taylor & Francis
Cancer radiotherapy (RT) may induce what is referred to as the “abscopal effect,” a regression
of non-irradiated metastatic lesions distant from the primary tumor site directly subject to …

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active …

…, F Marchesi, G Piaggio, D Giannarelli… - Journal of hematology & …, 2021 - Springer
Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in
hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (…

Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features

…, R Foa, R Cerretti, D Giannarelli… - Blood, The Journal …, 2000 - ashpublications.org
Fifty-two cases of autoimmune hemolytic anemia (AHA) were observed within a series of
1203 patients (4.3%) with chronic lymphocytic leukemia (CLL) followed at a single institution. …

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

…, O Di Bella, S Di Martino, F Ensoli, D Giannarelli… - …, 2021 - thelancet.com
Background Literature data suggests that age, gender and body mass index (BMI) could be
associated with difference in immune responses to vaccines. The first goal of the study was …

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

M Capone, D Giannarelli, D Mallardo… - … for immunotherapy of …, 2018 - Springer
Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR)
is prognostic for worse outcomes in patients with a variety of solid cancers, including …